What’s New (and What’s Next) in Compounding Law | August 20, 2026
EDUCON 2026
POWERED BY LP3 NETWORK
Overview
This session explores emerging legal developments shaping compounding pharmacy practice, including collaborative practice agreements, expanding pharmacist prescriptive authority, and evolving telemedicine frameworks. It will also introduce the concept of Just Culture and its role in regulatory and compliance decision-making. Attendees will leave with a practical understanding of what’s changing now and what to watch for next.
Intended audience
- Pharmacists & Pharmacy Technicians
Learning Objectives
Pharmacists and Pharmacy Technicians
Coming soon.
Hardware/software requirements
We will be using Zoom for this webinar - full system requirements can be found here. You can download the Zoom client here.
Web browser |
| ||
Internet connection |
| ||
Misc |
| ||
Hardware | Minimum | Recommended | |
| Processor | Single-core 1Ghz or higher | Dual-core 2Ghz or higher (Intel i3/i5/i7 or AMD equivalent) | |
| RAM | N/A | 4 GB | |
COPYRIGHT
This webinar is Copyright © Alliance for Pharmacy Compounding 2026.
| Karla Palmer | ![]() |
As a litigator with over 30 years’ experience, Karla advises clients throughout the pharmaceutical supply chain – from manufacturers and distributors to outsourcing facilities, pharmacies and doctors – on a range of legal and regulatory issues. These matters include DEA and FDA regulations and guidance, government inspections and investigations, Form 483 observations, warning letters, consent decrees, and administrative and federal proceedings. She represents entities and individuals in matters involving their DEA registration, including investigations, orders to show cause, immediate suspension matters, hearings and federal appeals of the same. Karla is a nationally recognized leader in the compounding space, both for Section 503A and 503B facilities. She regularly counsels clients on all aspects of compliance with state and federal statutes, regulations and guidance. Karla has written about and addressed industry audiences across the country on FDA and compliance, including all aspects of the passage and implementation of the 2013 Drug Quality and Security Act including both compounding and supply chain issues, its guidance documents, and implementing regulations.

Facebook
X
LinkedIn
Forward